Ze Zhang Wenwen Zhang Hongguang Wang Bingyang Hu Zhanbo Wang Shichun Lu
10.3389/fimmu.2021.744571
Front Immunol
2021 Sep 17;12:744571.
pd-l1 tmb conversion therapy immunotherapy intrahepatic cholangiocarcinoma
CC BY
https://pubmed.ncbi.nlm.nih.gov/34603331/
Antineoplastic Combined Chemotherapy Protocols / therapeutic use Bile Duct Neoplasms / drug therapy
Antineoplastic Combined Chemotherapy Protocols / therapeutic use Bile Duct Neoplasms / drug therapy Case Reports Research Support, Non-U.S. Gov't Adult Antibodies, Monoclonal, Humanized / administration & dosage B7-H1 Antigen / biosynthesis Bile Duct Neoplasms / genetics Bile Duct Neoplasms / surgery Chemotherapy, Adjuvant / methods Cholangiocarcinoma / drug therapy Cholangiocarcinoma / genetics Cholangiocarcinoma / surgery Female Hepatitis B, Chronic / complications Humans Immune Checkpoint Inhibitors / administration & dosage Neoadjuvant Therapy / methods Phenylurea Compounds / administration & dosage Protein Kinase Inhibitors / administration & dosage Quinolines / administration & dosage Antibodies, Monoclonal, Humanized B7-H1 Antigen CD274 protein, human Immune Checkpoint Inhibitors Phenylurea Compounds Protein Kinase Inhibitors Quinolines sintilimab lenvatinib
PMC8484748
34603331
Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report
2021